DOCSLIB.ORG

Management of Frozen Shoulder: a Systematic Review and Cost-Effectiveness Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Frozen Shoulder: a Systematic Review and Cost-Effectiveness Analysis Health Technology Assessment 2012; Vol. 16: No.111 Acknowledgements Health Technology Assessment 2012; Vol. 16: No. 11 ISSNContribution 1366-5278 of authors ISSN 1366-5278 ReferencesAbstractAppendix 7.2 Sodium hyaluronate Appendix 7.3 Physical therapy GlossaryAppendixAppendix 1 7.4 Acupuncture (with or without physical therapy) SearchAppendix strategies 7.5 Manipulation for effectiveness under review anaesthesia 179 ListBIOSIS ofAppendix abbreviations Previews 7.6 Distension CumulativeAppendix Index7.7 Capsular to Nursing release and Allied Health Literature (CINAHL) ExecutiveCochrane summary Central Register of Controlled Trials (CENTRAL) Clinicaltrials.govBackgroundAppendix 8 CochraneObjectivesStudy quality Database of Systematic Reviews (CDSR) 369 ConferenceMethodsControlled Proceedings trials Citation Index: Science Management of frozen shoulder: DatabaseResultsObservational of Abstracts studies of Reviews of Effects (DARE) EMBASEConclusions a systematic review and HealthFundingAppendix Management 9 Information Consortium (HMIC) HealthWinBUGS Technology code Assessment (HTA) database 373 cost-effectiveness analysis Chapter 1 Latin American and Caribbean Health Sciences Literature (LILACS) BackgroundAppendix 10 Manual, Alternative and Natural Therapy (MANTIS) TheMixed-treatment decision problem comparison 375 NHS Economic Evaluation Database (NHS EED) FrozenNetwork shoulder 1: studies of any intervention (i.e. conservative and invasive) and any quality National Technical Information Service (NTIS) DiagnosisNetwork 2:and studies management of any intervention that were of good or satisfactory quality (i.e. method E Maund, D Craig, S Suekarran, AR Neilson, PASCAL Previousof randomisation systematic was reviews adequate and outcome assessment was blinded) Physiotherapy Evidence Database (PEDro) K Wright, S Brealey, L Dennis, L Goodchild, FocusNetwork of the 3: studiessynthesis of conservative treatments of any quality PREMEDLINE Network 4: studies of conservative treatments that were of good or satisfactory quality (i.e. Science Citation Index N Hanchard, A Rangan, G Richardson, Chaptermethod 2 of randomisation was adequate and outcome assessment was blinded) J Robertson and C McDaid AdditionalMethods quality of life search strategy for information to inform the decision-analytic model OverviewAppendix 11 Appendix 2 ReviewEconomic of clinical evaluation effectiveness study quality and checklistcost-effectiveness 383 Search strategy for review of views of people with frozen shoulder 233 Literature searches Cumulative Index to Nursing and Allied Health Literature (CINAHL) InclusionAppendix and 12 exclusion criteria MEDLINE ScreeningEconomic and evaluation study selection data extraction/summary 385 PsycINFO Data extraction Appendix 13 Assessment of risk of bias AppendixResource-use 3 table 387 Synthesis R Resourcecode for standard use for the deviation interventions identified from the primary studies included in the review237 Systematic review of patients’ views of interventions for frozen shoulder HealthAssessmentAppendix Technology 14 of cost-effectivenessAssessment programme Exploratory mapping analysis 389 ChapterAppendixMapping 3 4 from SF-36 PCS and MCS onto EQ-5D Results QualityMapping assessment from pain checklist visual analogue scale onto EQ-5D 245 Assessment of clinical effectiveness AppendixMixed-treatmentAppendix 5 15 comparison results ListPatients’Protocol of excluded views studiesof interventions for frozen shoulder 247403 EconomicResearch analyses protocol 1.1 Appendix 6 Decision1. Research model objectives Study details 263 2. Background Appendix 6.1 Steroid injection Chapter3. Research 4 methods AppendixDiscussion 6.2 Sodium hyaluronate 4. Advisory Group AppendixPrincipal 6.3findings Acupuncture 5. Project timetable and milestones AppendixStrengths 6.4 and Physical limitations therapy of the review March 2012 6. References AppendixImproving 6.5 the Manipulation evidence on underthe effectiveness anaesthesia and cost-effectiveness Appendix A Rapid appraisal search to identify systematic reviews, published and in 10.3310/hta16110 Appendix 6.6 Distension progress, guidelines and ongoing primary research ChapterAppendix 5 6.7 Capsular release ConclusionsAppendix B Search strategy AppendixImplicationsAppendix 7 C for Quality service assessment provision Case series quality rating Health Technology Assessment DataSuggested extraction research tables priorities 291 Appendix 7.1 Steroid injection NIHR HTA programme www.hta.ac.uk HTA How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below). Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents. Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order: – fax (with credit card details) – post (with credit card details or cheque) – phone during office hours credit( card only). Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows: Synergie UK (HTA Department) Email: [email protected] Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’ Wade Road (out-of-hours answer-phone service) Basingstoke Hants RG24 8QW Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header Payment methods Paying by cheque If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit card You can order using your credit card by phone, fax or post. Subscriptions NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD? Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide. The website also provides information about the HTA programme and lists the membership of the various committees. Management of frozen shoulder: a systematic review and cost-effectiveness analysis E Maund,1 D Craig,1 S Suekarran,1 AR Neilson,1 K Wright,1 S Brealey,2 L Dennis,3 L Goodchild,4 N Hanchard,3 A Rangan,5 G Richardson,6 J Robertson7 and C McDaid1* 1Centre for Reviews and Dissemination, University of York, York, UK 2Department of Health Sciences, University of York, York, UK 3School of Health & Social Care, Teesside University, Middlesbrough, UK 4Department of Rehabilitation, The James Cook University Hospital, Middlesbrough, UK 5The James Cook University Hospital, Middlesbrough, UK 6Centre for Health Economics, University of York, York, UK 7Cambridge Medical Group, Middlesbrough, UK *Corresponding author Declared competing interests of authors: Amar Rangan has received consultancy fees from DePuy International relating to shoulder replacement prostheses. A division of DePuy is involved in marketing products for surgical treatment of the frozen shoulder. The other authors report no conflicts of interest. Published March 2012 DOI: 10.3310/hta16110 This report should be referenced as follows: Maund E, Craig D, Suekarran S, Neilson AR, Wright K, Brealey S, et al. Management of frozen shoulder: a systematic review and cost-effectiveness analysis. Health Technol Assess 2012;16(11). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch) and Current Contents/ Clinical Medicine. ii NIHR Health Technology Assessment programme The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender. Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These
Load more

Recommended publications
  • WHO Pharmaceuticals Newsletters
    2021 WHO Pharmaceuticals No.1 NEWSLETTER The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicines WHO Vision for Medicines Safety and legal actions taken by regulatory authorities around No country left behind: the world. It also provides signals based on information worldwide pharmacovigilance for safer medicines, safer patients derived from the WHO global database of individual case safety reports, VigiBase. In addition, this edition of the Newsletter includes a The aim of the Newsletter is to disseminate regulatory summary of discussions and key recommendations of information on the safety of Advisory Committee on Safety of Medicinal Products pharmaceutical products, (ACSoMP) Seventeenth meeting. based on communications received from our network of national pharmacovigilance centres and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from: Safety and Vigilance: Medicines, EMP-HIS, World Health Organization, 1211 Geneva 27, Switzerland, Contents E -mail address: [email protected] This Newsletter is also available at: Regulatory matters http://www.who.int/medicines Safety of medicines Signal Feature WHO Pharmaceuticals Newsletter No. 1, 2021 ISBN 978-92-4-002136-5 (electronic version) ISBN 978-92-4-002137-2 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • The Opportunities and Challenges of Pragmatic Point-Of-Care Randomised Trials Using Routinely Collected Electronic Records: Evaluations of Two Exemplar Trials
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 18 ISSUE 43 JULY 2014 ISSN 1366-5278 The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials Tjeerd-Pieter van Staa, Lisa Dyson, Gerard McCann, Shivani Padmanabhan, Rabah Belatri, Ben Goldacre, Jackie Cassell, Munir Pirmohamed, David Torgerson, Sarah Ronaldson, Joy Adamson, Adel Taweel, Brendan Delaney, Samhar Mahmood, Simona Baracaia, Thomas Round, Robin Fox, Tommy Hunter, Martin Gulliford and Liam Smeeth DOI 10.3310/hta18430 The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials Tjeerd-Pieter van Staa,1,2* Lisa Dyson,3 Gerard McCann,4 Shivani Padmanabhan,4 Rabah Belatri,4 Ben Goldacre,1 Jackie Cassell,5 Munir Pirmohamed,6 David Torgerson,3 Sarah Ronaldson,3 Joy Adamson,3 Adel Taweel,7 Brendan Delaney,7 Samhar Mahmood,7 Simona Baracaia,7 Thomas Round,7 Robin Fox,8 Tommy Hunter,9 Martin Gulliford10 and Liam Smeeth1 1Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK 2Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands 3York Trials Unit, York University, York, UK 4Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK 5Division of Primary Care and Public Health, Brighton and Sussex Medical School, University of Brighton, Brighton, UK 6The Wolfson Centre for
    [Show full text]
  • Principios Activos Fotosensibles
    PRINCIPIOS ACTIVOS FOTOSENSIBLES PROTEGE A TUS PRODUCTOS DE LA FOTODEGRADACIÓN PRINCIPIOS ACTIVOS FOTOSENSIBLES Adenosine Carbamazepine Digitoxin Heptacaine Methaqualone-1-oxide Phenothiazines Sulfisomidine Tinidazole Vitamin D Adrenaline Carbisocaine Digoxin Hexachlorophane Methotrexate Phenylbutazone Sulpyrine Tolmetin Vitamin E Adriamycin Carboplatin Dihydroergotamin Hydralazine Metronidazole Phenylephrine Suprofen Tretinoin Vitamin K1 Amidopyrin Carmustine Dihydropyridines Mifepristone Phenytoin Triamcinolone Vitamin K2 Hydrochlorothiazide Suramin Amidinohydrazones Cefotaxime Diltiazem Hydrocortisone Minoxidil Physostigmine Triamterene Warfarin Amiloride Cefuroxime axetil Diosgenin Mitomycin C Piroxicam Tauromustine (TCNU) Trifluoperazine Hydroxychloroquine Terbutaline 4-Aminobenzoic acid Cephaeline Diphenhydramine Hypochloride Mitonafide Pralidoxime Trimethoprim Aminophenazone Cephalexine Dipyridamole Ibuprofen Mitoxantrone Prednisolone Tetracyclines Ubidecarenone Thiazide Aminophylline Cephradine Dithranol Imipramin Molsidomine Primaquine Vancomycin Thiocolchicoside Aminosalicylic acid Chalcone Dobutamin Indapamide Morphine Proguanil Vinblastine Thioridazine Amiodarone Chloramphenicol Dopamine Indomethacin Nalidixic acid Promazine Vitamin A Thiorphan Amodiaquine Chlordiazepoxide Dothiepin Indoprofen Naproxen Promethazine Vitamin B (see also Thiothixene Amonafide Chloroquine Doxorubicin Isoprenaline Neocarzinostatin Proxibarbital riboflavine) Tiaprofenic acid Amphotericin B Chlorpromazine DTIC Isopropylamino- Nimodipine Psoralen
    [Show full text]
  • Homeopathy Works, Then Obviously the Less You Use It, the Stronger It Gets
    http://www.physics.smu.edu/pseudo "...for the purposes of popular discourse, it is not necessary for homeopaths to prove their case. It is merely necessary for them to create walls of obfuscation, and superficially plausible technical documents that support their case, in order to keep the dream alive in the imaginations of both the media and their defenders." --Ben Goldacre If homeopathy works, then obviously the less you use it, the stronger it gets. So the best way to apply homeopathy is to not use it at all. --Phil Plait http://www.physics.smu.edu/pseudo “Alternative Medicine” - Homeopathy - Supplementary Material for CFB3333/PHY3333 Professors John Cotton, Randy Scalise, and Stephen Sekula http://www.physics.smu.edu/pseudo ● FRINGE ● The land of wild ideas, mostly untested or untestable. Most of these will be discarded as useless. Only some of these will make it into the frontier. ● FRONTIER ● CORE Tested (somewhat or better) ideas that could still be wrong or require significant modification. ● CORE FRONTIER ● Very well-tested ideas that are unlikely to be overturned. They may FRINGE become parts of bigger ideas, but are very unlikely to be discarded. A Depiction of Science Thanks to Eugenie Scott http://www.physics.smu.edu/pseudo HOMEOPATHY A LOOK AT THE SCIENTIFIC EVIDENCE http://www.physics.smu.edu/pseudo Claim and Assessment ● Claim: homeopathic medicine can treat the diseases it claims to treat ● there are many more medicines than there have been scientific tests of those medicines, which should already tell you something. Homeopathy is like a hydra. ● Tests: ● Gold-standard medical testing: randomized, double/single-blinded, placebo-controlled, large-statistics trials http://www.physics.smu.edu/pseudo http://www.physics.smu.edu/pseudo ● Findings: ● 8 studies in the review fulfilled their review criteria ● Only about half of those were more akin to gold standard, and they tended to show no effect over placebo.
    [Show full text]
  • Transparency in the Time of Constant Change
    PhUSE 2014 Paper RG02 Transparency in the Time of Constant Change Todd Case, Biogen Idec, Cambridge MA, USA ABSTRACT The time has come, after years of hard work, to submit your application to the regulatory agency for review and possible approval! What a relief to be able to finally hand off all of your hard work and, wait a minute, ensure that all data can be reproducible?!? While CDISC has been widely adopted and its SDTM and AdAM models widely implemented, there is still the need to understand the process of ensuring that all the data is a reflection of how it was originally collected, which in some cases can be very challenging. This paper will discuss some more trending ways of both creating and presenting data in ways that ensure it is consumable and can be understood not only for analysis/submission purposes but also that post-approval it is transparent and that everyone who has a vested stake can review the data in an appropriate way. INTRODUCTION With the publication of Bad Pharma: How Medicine is Broken , and How We Can Fix it, by Dr. Ben Goldacre in 2013 a bright spotlight was shone on the data behind/supporting clinical trials. A large part of his thesis is that pharmaceutical companies exaggerate the efficacy of successful trials and that, in addition to drug companies, regulators , physicians (who are educated by the drug companies) and even patient groups have failed to protect us. Another rather striking revelation was that a clinical trial with positive results is twice more likely to be published than one with negative results (although it should be noted that this specifically is related to results – the protocol is always provided).
    [Show full text]
  • Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients by Ben Goldacre
    RCSIsmjbook review Bad Pharma: How drug companies mislead doctors and harm patients by Ben Goldacre Reviewed by Eoin Kelleher, RCSI medical student Paperback: 448 pages Publisher: Fourth Estate, London Published 2012 ISBN: 978-0-00-735074-2 Dr Ben Goldacre earned his reputation for his 2008 book Bad to affect doctors’ prescribing habits (although most doctors claim Science and his column in the Guardian newspaper of the same that their own practices have never been affected, just those of their name. In both he provides an entertaining, accessible and colleagues). Even journals, which are considered to be an unbiased well-researched exposé of poor scientific practices. Compared to source of medical knowledge, are not free from this – journal articles his first book, which played charlatans such as Gillian McKeith are regularly ghost-written by employees of drug companies and an and homoeopathists for laughs, Bad Pharma is a much more eminent academic is invited to put their name to it; this appears in sombre read. However, as a piece of investigative journalism, and the journal, again without disclosure. a resource for students, doctors and patients, it is invaluable. Drugs are tested by the people who Food for thought Goldacre opens by making a claim that: “Drugs are tested by the manufacture them, in poorly designed people who manufacture them, in poorly designed trials, on trials, on hopelessly small numbers of hopelessly small numbers of weird, unrepresentative patients, and unrepresentative patients, and analysed analysed using techniques which are flawed by design, in such a way that exaggerate the benefits of treatments.
    [Show full text]
  • Drugs, Money and Misleading Evidence
    Books & arts tallying up the inequalities. She recruited colleagues to gather much more data. The culmination was a landmark 1999 study on gender bias in MIT’s school of science (see go.nature.com/2ngyiyd), which reverber- ated across US higher education and forced many administrators to confront entrenched discrimination. Yet Hopkins would rather have spent that time doing science, she relates. The third story comes from Jane Willenbring, a geoscientist who in 2016 filed a formal com- plaint accusing her PhD adviser, David March- ant, of routinely abusing her during fieldwork in Antarctica years before. Marchant, who has denied the allegations, was sacked from his post at Boston University in April 2019 after an inves- tigation. Picture a Scientist brings Willenbring together with Adam Lewis, who was also a grad- uate student during that Antarctic field season and witnessed many of the events. Their conver- sations are a stark reminder of how quickly and how shockingly the filters that should govern work interactions can drop off, especially in UPRISING, LLC Biologist Nancy Hopkins campaigned for equal treatment at work for female scientists. remote environments. Lewis tells Willenbring he didn’t realize at the time that she had been as they admit on camera. scientists. Its two other protagonists are white bothered, because she did not show it. “A ton The iceberg analogy for sexual harassment is women with their own compelling stories. of feathers is still a ton,” she says. apt. It holds that only a fraction of harassment — Biologist Nancy Hopkins was shocked In stark contrast, the film shows us obvious things such as sexual assault and sex- when Francis Crick once put his hands on Willenbring, now at the Scripps Institution of ual coercion — rises into public consciousness her breasts as she worked in the laboratory.
    [Show full text]
  • Philip Mirowski, Never Let a Serious Crisis Go to Waste: How Neoliberalism Survived the Financial Meltdown, New York: Verso, 2013
    Book Review Symposium Philip Mirowski, Never Let a Serious Crisis Go to Waste: How Neoliberalism Survived the Financial Meltdown, New York: Verso, 2013. ISBN: 9781781680797 (cloth); ISBN: 9781781683033 (ebook); ISBN: 9781781683026 (paper) Author’s response I want to thank Antipode and the four participants for lengthy reactions to my book Never Let a Serious Crisis Go to Waste. I think it is apparent it was written in a funk of distress; and the reviewers here invite me to step back from all that, and reflect on how it has been regarded by various readers who do not necessarily share my own particular chagrin nor my axes to grind. The experience has been salutary, and evokes a few short responses. One theme present to a greater or lesser extent in all the reviews is that, as Nick Gane puts it, I never tell the reader “what should happen next”; or, as Geoff Mann writes, “OK. So what now?”. I should confess I also get this a lot when I give talks concerning the subjects in the book. When that happens, I take the occasion to suggest that one of the primary lessons of the book directly informs my self-denying ordinance: the prohibition of offering any ‘remedies’ as conventional bullet points, like those which fill the last chapters of the torrent of crisis books which have fallen from the presses clonedead since 2008. When the Neoliberal Thought Collective (NTC) began to organize itself in the 1930s/40s, it found itself stranded in the intellectual wilderness, exiled from political power by Depression and war, and suffering internal disarray, much as the Left has experienced now.
    [Show full text]
  • Myofascial Pain Syndrome: a Treatment Review Mehul J
    Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Anesthesiology and Critical Care Medicine Faculty Anesthesiology and Critical Care Medicine Publications 6-2013 Myofascial pain syndrome: A treatment review Mehul J. Desai George Washington University Vikramjeet Saini Shawnjeet Saini Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_anesth_facpubs Part of the Anesthesia and Analgesia Commons Recommended Citation Desai, M. J., Saini, V., & Saini, S. (2013). Myofascial Pain Syndrome: A Treatment Review. Pain and Therapy, 2(1), 21–36. This Journal Article is brought to you for free and open access by the Anesthesiology and Critical Care Medicine at Health Sciences Research Commons. It has been accepted for inclusion in Anesthesiology and Critical Care Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please contact [email protected]. Pain Ther (2013) 2:21–36 DOI 10.1007/s40122-013-0006-y REVIEW Myofascial Pain Syndrome: A Treatment Review Mehul J. Desai • Vikramjeet Saini • Shawnjeet Saini To view enhanced content go to www.paintherapy-open.com Received: September 27, 2012 / Published online: February 12, 2013 Ó The Author(s) 2013. This article is published with open access at Springerlink.com ABSTRACT and nonpharmacologic treatments, the authors aim to provide clinicians with a more Myofascial pain syndrome (MPS) is defined as comprehensive knowledge of the interventions pain that originates from myofascial trigger for myofascial pain. points in skeletal muscle. It is prevalent in regional musculoskeletal pain syndromes, either alone or in combination with other pain Keywords: Analgesics; Anticonvulsants; generators. The appropriate evaluation and Muscle relaxants; Myofascial pain; management of myofascial pain is an important Nonpharmacological treatment; Pain; part of musculoskeletal rehabilitation, and Treatment regional axial and limb pain syndromes.
    [Show full text]
  • Treatment for Acute Pain: an Evidence Map Technical Brief Number 33
    Technical Brief Number 33 R Treatment for Acute Pain: An Evidence Map Technical Brief Number 33 Treatment for Acute Pain: An Evidence Map Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-0000-81 Prepared by: Minnesota Evidence-based Practice Center Minneapolis, MN Investigators: Michelle Brasure, Ph.D., M.S.P.H., M.L.I.S. Victoria A. Nelson, M.Sc. Shellina Scheiner, PharmD, B.C.G.P. Mary L. Forte, Ph.D., D.C. Mary Butler, Ph.D., M.B.A. Sanket Nagarkar, D.D.S., M.P.H. Jayati Saha, Ph.D. Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19(20)-EHC022-EF October 2019 Key Messages Purpose of review The purpose of this evidence map is to provide a high-level overview of the current guidelines and systematic reviews on pharmacologic and nonpharmacologic treatments for acute pain. We map the evidence for several acute pain conditions including postoperative pain, dental pain, neck pain, back pain, renal colic, acute migraine, and sickle cell crisis. Improved understanding of the interventions studied for each of these acute pain conditions will provide insight on which topics are ready for comprehensive comparative effectiveness review. Key messages • Few systematic reviews provide a comprehensive rigorous assessment of all potential interventions, including nondrug interventions, to treat pain attributable to each acute pain condition. Acute pain conditions that may need a comprehensive systematic review or overview of systematic reviews include postoperative postdischarge pain, acute back pain, acute neck pain, renal colic, and acute migraine.
    [Show full text]
  • Histories of Medical Lobbying’
    ‘Histories of medical lobbying’ The lobbying of government ministers by medical professionals is a live issue. In Britain and around the world medical practitioners have become active in the pursuit of legislative change. In the UK, the AllTrials campaign co-founded by the physician-researcher Ben Goldacre continues to exert pressure on parliamentarians in a bid to force greater transparency in the publication of clinical trial results. Meanwhile, the California Medical Association advocates the legalisation of the recreational use of marijuana, and doctors in Australia refuse to release child refugees from hospital into detention centres damaging to their mental health. It was precisely the lobbying of medical humanitarians such as Médecins sans Frontières in France that effected a change in the law there in 1998, permitting undocumented immigrants with life-threatening conditions to remain in the country for medical treatment. Each of these examples represents an organised attempt on the part of medical professionals to change government policy on matters related to public health – in other words, lobbying. Yet a recent announcement by the UK cabinet office suggests that henceforth recipients of public funding will be banned from directly lobbying government ministers in the hope of changing public policy. When questioned in parliament David Cameron stated that charities should be devoting themselves to ‘good causes’ rather than ‘lobbying ministers’. Unless some qualification is forthcoming, medical researchers too will be proscribed from carrying out such activity. This insinuates that lobbying is in some way outside the proper remit of researchers, medical or otherwise. Yet even a cursory glance at the history of the medical profession’s engagement with public health reveals a longstanding and significant engagement with the political process.
    [Show full text]